Shelter Island, NY, United States of America

Helen Vlassara

This inventor holds 25 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent, primarily in Advanced Glycosylation. Top assignees: The Picower Institute for Medical Research, The Rockefeller University, Alteon Incorporated. Active years: 1983-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Helen Vlassara. Retrieved from https://idiyas.com/inventor/helen-vlassara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 

% Patents Active = 100.0


 

Average Co-Inventor Count = 3.3

ph-index = 15

Forward Citations = 499(Granted Patents)


Location History:

  • Shelter Island, NJ (US) (1999)
  • Shelter Island, NY (US) (1997 - 2002)
  • New York, NY (US) (1983 - 2015)

Company Filing History:


Years Active: 1983-2015

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Anti-TNF-α Therapy
Amyloidosis
Glycosylation
Advanced Glycosylation Endproducts
Lysosomal Disorders
Diagnostic Methods
Treatment Methods
Metabolic Control
Pentosan Polysulfate
Receptors
Partitioning
Inhibition
25 patents (USPTO):Explore Patents

Title: Innovation and Impact: The Patents and Career of Helen Vlassara

Introduction

Helen Vlassara, based in Shelter Island, NY, is a renowned inventor with a remarkable portfolio of 25 patents. Her work primarily focuses on innovative therapies for lysosomal disorders, showcasing her commitment to advancing medical research and treatment options.

Latest Patents

Among her latest patents is the invention titled "Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders." This innovative method involves administering an agent for enzyme replacement therapy combined with anti-TNF-α therapy to treat subjects with lysosomal disorders effectively. Additionally, her patent on the "Inhibition of TNF-α induced activation of NFKB by pentosan polysulfate" highlights the therapeutic potential of oral pentosan polysulfate (PPS) compositions in treating diseases such as diabetes, inflammation, and atherosclerosis while effectively reducing matrix metalloproteinases (MMPs).

Career Highlights

Helen has significantly contributed to the field of medical research through her tenure at prestigious institutions. She has worked with The Picower Institute for Medical Research and The Rockefeller University, where she collaborated on groundbreaking research projects. Her expertise in lysosomal disorders has solidified her reputation as a leading figure in the medical innovation landscape.

Collaborations

Throughout her career, Helen Vlassara has collaborated with notable figures in the medical research community. Notable coworkers include Anthony Cerami and Richard J. Bucala, both of whom have made significant contributions to advancements in biological science and therapeutics.

Conclusion

Helen Vlassara's extensive patent portfolio and her impactful career in medical research underscore her dedication to innovation. Her work not only opens new avenues for therapy in lysosomal disorders but also exemplifies the critical role of inventors in driving advancements within the healthcare field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…